Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0S4II
|
||||
Former ID |
DCL000407
|
||||
Drug Name |
GSK1292263
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Gastric cancer; Type 2 diabetes [ICD9: 151, 250; ICD10:C16, E11] | Phase 2 | [523205] | ||
Company |
GSK
|
||||
Structure |
Download2D MOL |
||||
Formula |
C24H30N4O4S
|
||||
Canonical SMILES |
CC(C)C1=NOC(=N1)N2CCC(CC2)CCOC3=CN=C(C=C3)C4=CC=C(C=C4)<br />S(=O)(=O)C
|
||||
InChI |
1S/C24H30N4O4S/c1-17(2)23-26-24(32-27-23)28-13-10-18(11-14-28)12-15-31-20-6-9-22(25-16-20)19-4-7-21(8-5-19)33(3,29)30/h4-9,16-18H,10-15H2,1-3H3
|
||||
InChIKey |
HWRHYSUKHZYCAU-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Glucose-dependent insulinotropic receptor | Target Info | Modulator | ||
KEGG Pathway | cAMP signaling pathway | ||||
Insulin secretion | |||||
WikiPathways | Incretin Synthesis, Secretion, and Inactivation | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.